Skip to content

Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.

Simon L Hill, Javad Najafi, Michael Dunn, Paul Acheampong, Ashraf Kamour, Johann Grundlingh, Peter G Blain, Simon H L Thomas

Clinical toxicology (Philadelphia, Pa.) September 1, 2016 DOI: 10.1080/15563650.2016.1190980 via PubMed

Summary

AI-generated from the abstract

In seven men who presented to hospitals in England between July and October 2015 after smoking 'legal high' products, analytically confirmed exposure to the synthetic cannabinoid receptor agonist MDMB-CHMICA was associated with acidosis (respiratory in three, metabolic in three, mixed in one), reduced level of consciousness (six of seven), dilated pupils (five of seven), fast heart rate (five of seven), slow heart rate (two of seven), convulsions (two of seven), and agitation (three of seven). Recovery occurred within 24 hours in all but one case where methiopropamine was also present.

Study at a glance

Characteristics Case series Case report Peer reviewed
Sample size 7
Population Men with severe toxicity after suspected use of novel psychoactive substances in England
Keywords Mdmb-chmica Methiopropamine Toxicity
Key finding Analytically confirmed exposure to MDMB-CHMICA was associated with acidosis, reduced level of consciousness, mydriasis, heart rate disturbances, and convulsions.

Abstract

Recreational use of Synthetic Cannabinoid Receptors Agonists (SCRAs) has become increasingly common in many countries and may cause severe toxic effects. To describe the clinical features of toxicity in seven men after analytically confirmed exposure to MDMB-CHMICA, a recently described indole-based SCRA. Clinical information and biological samples (blood, urine) were collected from patients with severe toxicity after suspected use of novel psychoactive substances. Samples were analyzed by data-independent liquid chromatography-tandem mass spectrometry (LC-MS/MS). All seven cases were men who presented to hospitals in England between July and October 2015; six reported smoking "legal high" products. In all cases, MDMB-CHMICA was identified in blood samples taken on admission to hospital. Other substances were identified in four cases (methadone 1, methiopropamine 1, other SCRAs 2). Clinical features in all seven cases and in the three exposed to MDMB-CHIMICA alone included acidosis (7/7 and 3/3) which was respiratory (3/7 and 3/3), metabolic (3/7 and 0/3) or mixed (1/7, 0/3), reduced level of consciousness (6/7 and 3/3), mydriasis (5/7 and 3/3), tachycardia (5/7 and 2/3), bradycardia (2/7 and 1/3), tonic-clonic convulsions (2/7 and 1/3) and agitation (3/7 and 1/3). Recovery occurred within 24 h in all cases except one male also exposed to methiopropamine. Analytically confirmed exposure to MDMB-CHMICA was associated with acidosis (often of respiratory origin), reduced level of consciousness, mydriasis, heart rate disturbances and convulsions.

Comments

No comments yet.

Log in to comment